ArticleJournal of medical case reports2026
A fatal pediatric case of febrile ulceronecrotic Mucha-Habermann disease: diagnostic and therapeutic challenges: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFebrile ulceronecrotic Mucha-Habermann Disease (FUMHD) is a rare and severe form of pityriasis lichenoides et varioliformis acuta. It presents rapidly with ulcerative and necrotic lesions, fever, and systemic symptoms. This condition is associated with significant morbidity and can be extremely dangerous. The exact cause of FUMHD is not well understood, but hypersensitivity reactions may trigger it. CASE PRESENTATION: We describe a 15-month-old Iranian boy who developed rapidly progressing ulceronecrotic skin lesions accompanied by high-grade fever and systemic involvement. A skin biopsy confirmed a diagnosis of FUMHD. Despite treatment with methylprednisolone, intravenous immunoglobulin, and a TNF-α inhibitor, the disease was fatal. To our knowledge, this represents the third reported fatal case of FUMHD in children and the youngest case documented to date.
conclusionThis report presents the youngest known pediatric case of fatal FUMHD, highlighting the challenges of early diagnosis, risk of systemic infection, and limited treatment options. Early immunosuppressive and antimicrobial therapies are crucial, but prognosis remains poor in aggressive cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.